Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LRRK2 -associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization

1 Jan 2025

Abstract excerpt

Abstract Among LRRK2-associated parkinsonism cases with nigral degeneration, over two-thirds demonstrate evidence of pathologic alpha-synuclein, but many do not. Understanding the clinical phenotype and underlying biology in such individuals is critical for therapeutic development. Our objective was to compare clinical and biomarker features, and rate of progression over 4 years of follow-up, among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurological diseases and metabolism
Share to Parkinson's Disease and Spinal Disorders
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40114783
DOI: 10.1093/braincomms/fcaf103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LRRK2 -associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationPMID 40114783Read ↗

LRRK2-Associated Parkinsonism With and Without<i>In Vivo</i>Evidence of Alpha-Synuclein AggregatesSemantic proximity Read ↗

Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional studySemantic proximity Read ↗

Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson’s disease in the PPMI cohortSemantic proximity Read ↗

Diagnostic and prognostic value of alpha-synuclein seed amplification assay in Parkinson’s disease: a longitudinal cohort studySemantic proximity Read ↗

SAA positivity rate amongst dual LRRK2-GBA1, GBA1 and LRRK2 carriers with Parkinson’s diseaseSemantic proximity Read ↗

Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-Synuclein Seeding ActivitySemantic proximity Read ↗

Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical DataSemantic proximity Read ↗

Synuclein and dopamine transporter biomarkers among phenoconverters to parkinsonian disordersSemantic proximity Read ↗

Genome-wide association studies identify genetic determinants of synucleinopathy biomarkers.Semantic proximity Read ↗

Neuropathology in genetic Parkinson's disease: a focused review of pathological and clinical findings.Semantic proximity Read ↗

The α-Synuclein seeding assay discriminates between LRRK2 p.Gly2019Ser variant carriers with and without Parkinson’s diseaseSemantic proximity Read ↗

Faster reaction times of CSF Alpha-Synuclein Seed Amplification Assay predict the Diffuse Malignant subtype of Parkinson’s Disease at 10-year follow-upSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.